{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T11:04:23Z","timestamp":1790507063414,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.humpath.2021.12.011","type":"journal-article","created":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T07:28:10Z","timestamp":1641799690000},"page":"56-64","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["SOX9 and SATB2 immunohistochemistry cannot reliably distinguish between osteosarcoma and chondrosarcoma on biopsy material"],"prefix":"10.1016","volume":"121","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3088-3946","authenticated-orcid":false,"given":"Aarti E.","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Pytel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3092-2746","authenticated-orcid":false,"given":"Nicole A.","family":"Cipriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2021.12.011_bib1","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1080\/13543784.2016.1237503","article-title":"Drugs in early clinical development for the treatment of osteosarcoma","volume":"11","author":"Heymann","year":"2016","journal-title":"Expet Opin Invest Drugs"},{"key":"10.1016\/j.humpath.2021.12.011_bib2","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1302\/0301-620X.101B6.BJJ-2018-1090.R1","article-title":"Treatment outcome of patients with chondroblastic osteosarcoma of he limbs and pelvis","volume":"6","author":"Tsagozis","year":"2019","journal-title":"Bone Joint J"},{"key":"10.1016\/j.humpath.2021.12.011_bib3","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/MOP.0000000000000298","article-title":"Future directions in the treatment of osteosarcoma","volume":"1","author":"Bishop","year":"2016","journal-title":"Curr Opin Pediatr"},{"key":"10.1016\/j.humpath.2021.12.011_bib4","doi-asserted-by":"crossref","first-page":"151654","DOI":"10.1016\/j.anndiagpath.2020.151654","article-title":"Osteosarcoma: a comprehensive review of management and treatment strategies","volume":"49","author":"Jafari","year":"2020","journal-title":"Ann Diagn Pathol"},{"key":"10.1016\/j.humpath.2021.12.011_bib5","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.2106\/JBJS.H.00416","article-title":"Chondrosarcoma in the United States (1973 to 2003): an analysis of 2890 cases from the SEER database","volume":"5","author":"Giuffrida","year":"2009","journal-title":"J Bone Joint Surg Am"},{"key":"10.1016\/j.humpath.2021.12.011_bib6","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1634\/theoncologist.2007-0237","article-title":"The clinical approach towards chondrosarcoma","volume":"3","author":"Gelderblom","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.humpath.2021.12.011_bib7","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S1470-2045(05)70282-5","article-title":"Emergng pathays in the development of chondrosarcoma of bone and implications for targeted treatment","volume":"8","author":"Bovee","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.humpath.2021.12.011_bib8","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00428-008-0692-8","article-title":"Ezrin immunohistochemical expression in cartilaginous tumours: a useful tool for differential diagnosis between chondroblastic osteosarcoma and chondrosarcoma","volume":"1","author":"Salas","year":"2009","journal-title":"Virchows Arch"},{"key":"10.1016\/j.humpath.2021.12.011_bib9","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.humpath.2009.10.028","article-title":"Galectin-1 is a powerful marker to distinguish chondroblastic osteiosarcoma and conventional chondrosarcoma","volume":"9","author":"Gomez Brouchet","year":"2010","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2021.12.011_bib10","first-page":"409","article-title":"Osteonectin \u2013 a differentiation marker of bone cells","volume":"2","author":"Jundt","year":"1987","journal-title":"Cell Tissue Res"},{"key":"10.1016\/j.humpath.2021.12.011_bib11","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/0046-8177(92)90050-D","article-title":"Evaluation of osteonectin as a diagnostic marker of osteogenic bone tumors","volume":"12","author":"Serra","year":"1992","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2021.12.011_bib12","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0046-8177(99)90297-6","article-title":"Osteocalcin and osteonectin immunoreactivity in exraskeletal osteosarcoma: a study of 28 cases","volume":"1","author":"Fanburg-Smith","year":"1999","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2021.12.011_bib13","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/PAI.0b013e3181daace3","article-title":"A tissue microarray study of osteosarcoma: histopathologic and immunohistochemical validation of xenotransplanted tumors a preclinical models","volume":"5","author":"Mayordomo","year":"2010","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.humpath.2021.12.011_bib14","first-page":"579","article-title":"Biomarkers of chondrosarcoma","volume":"7","author":"Jeong","year":"2019","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.humpath.2021.12.011_bib15","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.prp.2016.06.012","article-title":"The utility of SATB2 immunohistochemical expression in distinguishing between osteosarcomas and their malignant bone tumor mimickers, such as Ewing sarcomas and chondrosarcomas","author":"Machado","year":"2016","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.humpath.2021.12.011_bib16","series-title":"Soft tissue and bone tumors","year":"2020"},{"key":"10.1016\/j.humpath.2021.12.011_bib17","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1177\/1066896910367650","article-title":"SOX9 expression is not limited to chondroid neoplasms; variable occurrence in other soft tissue and bone tumors with frequent expression by synovial sarcomas","volume":"5","author":"Cajaiba","year":"2010","journal-title":"In J Surg Pathol"},{"key":"10.1016\/j.humpath.2021.12.011_bib18","doi-asserted-by":"crossref","first-page":"100300","DOI":"10.1016\/j.jbo.2020.100300","article-title":"The local and circulating SOX9 as a potential biomarker for the diagnosis of primary bone cancer","volume":"23","author":"Hosseini","year":"2020","journal-title":"J Bone Oncol"},{"key":"10.1016\/j.humpath.2021.12.011_bib19","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/his.12138","article-title":"SATB2 is a novel marker of osteoblastic differentiation in bone and soft tissue tumours","volume":"1","author":"Conner","year":"2013","journal-title":"Histopathology"},{"key":"10.1016\/j.humpath.2021.12.011_bib20","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/his.12911","article-title":"Special AT-rich sequence-binding protein 2 (SATB2) expression is sensitive but may no be specific for osteosarcoma as compared with other high-grade primary bone sarcomas","volume":"1","author":"Davis","year":"2016","journal-title":"Histopathology"},{"key":"10.1016\/j.humpath.2021.12.011_bib21","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/PGP.0000000000000301","article-title":"SATB2 expression is sensitive but not specific for osteosarcomatous components of gynecologic tract carcinosarcomas: a clinicopathologic study of 60 cases","volume":"36","author":"Sangoi","year":"2017","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.humpath.2021.12.011_bib22","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/path.2913","article-title":"IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours","volume":"224","author":"Amary","year":"2011","journal-title":"J Pathol"},{"key":"10.1016\/j.humpath.2021.12.011_bib23","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1097\/PAS.0b013e31827ab703","article-title":"Molecular distinction of chondrosarcoma from chondroblastic osteosarcoma through IDH1\/2 mutations","volume":"37","author":"Kerr","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2021.12.011_bib24","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s10014-012-0085-1","article-title":"Frequent IDH1\/2 mutations in intracranial chondrosarcoma: a possible diagnostic clue for its differentiation from chordoma","volume":"29","author":"Arai","year":"2012","journal-title":"Brain Tumor Pathol"},{"key":"10.1016\/j.humpath.2021.12.011_bib25","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.bone.2019.07.017","article-title":"Satb2 regulates proliferation and nuclear integrity of pre-osteoblasts","volume":"127","author":"Dowrey","year":"2019","journal-title":"Bone"},{"key":"10.1016\/j.humpath.2021.12.011_bib26","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1111\/j.1460-9568.2005.03897.x","article-title":"Novel transcription factor Satb2 interacts with matrix attachement region DNA elements in a tissue-specific manner and demonstrates cell-type dependent expression in the developing mouse CNS","volume":"21","author":"Britanova","year":"2005","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.humpath.2021.12.011_bib27","doi-asserted-by":"crossref","first-page":"9360","DOI":"10.1073\/pnas.1631288100","volume":"100","author":"Mori-Akiyama","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.humpath.2021.12.011_bib28","doi-asserted-by":"crossref","first-page":"5681","DOI":"10.1242\/dev.00808","article-title":"Neural crest development is regulated by the transcription factor SOX9","volume":"130","author":"Cheung","year":"2003","journal-title":"Development"},{"key":"10.1016\/j.humpath.2021.12.011_bib29","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/(SICI)1098-1004(1997)9:5<388::AID-HUMU2>3.0.CO;2-0","article-title":"Mutations in SRY and SOX9: testis-determining genes","volume":"9","author":"Cameron","year":"1997","journal-title":"Hum Mutat"},{"key":"10.1016\/j.humpath.2021.12.011_bib30","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1002\/humu.23888","article-title":"Dominant-negative SOX9 mutations in campomelic dysplasia","volume":"40","author":"Csukas","year":"2019","journal-title":"Hum Mutat"},{"key":"10.1016\/j.humpath.2021.12.011_bib31","doi-asserted-by":"crossref","first-page":"5394","DOI":"10.1093\/nar\/gkv426","article-title":"The SOX9 upstream region prone to chromosomal aberrations causing campomelic dysplasia contains multiple cartilage enhancers","volume":"23","author":"Yao","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.humpath.2021.12.011_bib32","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.biocel.2017.03.005","article-title":"SOX9: a genomic view of tissue specific expression and action","volume":"87","author":"Symon","year":"2017","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.humpath.2021.12.011_bib33","doi-asserted-by":"crossref","first-page":"167","DOI":"10.18632\/oncoscience.21","article-title":"Theranostic profiling for actionable aberrations in advanced high rik osteosarcoma with aggressive biology reveals high molecular diversity: the human fingerprint hypothesis","volume":"1","author":"Egas-Bejar","year":"2014","journal-title":"Oncoscience"},{"key":"10.1016\/j.humpath.2021.12.011_bib34","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1177\/1066896910367650","article-title":"SOX9 expression is not limited to chondroid neoplasms: variable occurrence in other soft tissue and bone tumors with frequent expression by synovial sarcomas","volume":"18","author":"Cajaiba","year":"2010","journal-title":"Int J Surg Pathol"},{"key":"10.1016\/j.humpath.2021.12.011_bib35","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/PAI.0000000000000809","article-title":"SOX9 immunohistochemistry in the distinction of angiomatoid fibrous histiocytoma from histologic mimics: diagnostic utility and pitfalls","volume":"28","author":"Berklite","year":"2020","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.humpath.2021.12.011_bib36","doi-asserted-by":"crossref","first-page":"13494","DOI":"10.1038\/s41598-017-13994-w","article-title":"TGF-beta signalling and PEG10 are mutually exclusive and inhibitory in chondrosarcoma cells","volume":"18","author":"Shinohara","year":"2017","journal-title":"Sci Rep"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817721002197?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817721002197?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T16:39:53Z","timestamp":1758645593000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817721002197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":36,"alternative-id":["S0046817721002197"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2021.12.011","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOX9 and SATB2 immunohistochemistry cannot reliably distinguish between osteosarcoma and chondrosarcoma on biopsy material","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2021.12.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}